DeutschNewstral
Article
jdsupra.com on 2020-03-19 01:35
Pfizer Moves to Dismiss Amgen’s Suit Over Proposed Neulasta Biosimilar
Related news
- Amgen Sues Pfizer Over Proposed Neulasta Biosimilarjdsupra.com
- Prosecution History Estoppel Bars Amgen’s Doctrine-of-Equivalents Infringement Claim Against Neulasta (Pegfilgrastim) Biosimilar Maker Coherusjdsupra.com
- Litigation Update: Genentech’s Motion to Dismiss Amgen’s Counterclaims Denied in Avastin Biosimilar Litigationjdsupra.com
- Genentech Seeks to Dismiss and Strike Amgen’s Counterclaims and Certain Defenses in Bevacizumab Biosimilar Litigationjdsupra.com
- PFDA declines to approve Novartis biosimilar for Amgen’s Neulastapacbiztimes.com
- PNovartis biosimilar works as well as Amgen’s Neulastapacbiztimes.com
- Biosimilars Development Updates: Mylan’s Pipeline, Coherus’s Adalimumab aBLA, Amgen’s Eculizumab Biosimilarjdsupra.com
- AbbVie and Pfizer Settle Adalimumab Biosimilar Patent Disputesjdsupra.com
- Pfizer’s Biosimilar Antitrust Lawsuit Survives Johnson & Johnson’s Motion to Dismissjdsupra.com
- PEuropeans recommend approval of Amgen’s biosimilar of AbbVie’s Humirapacbiztimes.com
- PFDA approves biosimilar of Amgen’s Neulastapacbiztimes.com
- New BPCIA Complaint: Amgen Sues Pfizer over Proposed Filgrastim Biosimilarjdsupra.com
- Pfizer Launches RETACRIT (Epoetin Alfa-epbx) Biosimilar in United Statesjdsupra.com
- EC Approves Amgen’s Biosimilar Adalimumabjdsupra.com
- BREAKING NEWS: Federal Circuit Affirms Amgen’s $70 Million Damages Award Against Pfizer Unitjdsupra.com
- Amgen Files New Patent Infringement Suit Over Neupogen Biosimilarjdsupra.com
- Pfizer Receives European Approval For Avastin® (Bevacizumab) Biosimilarjdsupra.com
- Amneal Seeks Dismissal as Defendant in Amgen v. Adello Filgrastim Biosimilar Suitjdsupra.com
- Proposed Amendment to Hatch-Waxman and BPCIA Could Curb IPRs by Generic and Biosimilar Applicants (Updated)jdsupra.com
- Amgen and Kashiv Ask District Court to Dismiss Their Filgrastim Biosimilar Litigationjdsupra.com